Elsevier

Clinics in Perinatology

Volume 41, Issue 4, December 2014, Pages 925-943
Clinics in Perinatology

Vascular Endothelial Growth Factor Antagonist Therapy for Retinopathy of Prematurity

https://doi.org/10.1016/j.clp.2014.08.011Get rights and content

Section snippets

Key points

  • Before considering anti-vascular endothelial growth factor (VEGF) agents in preterm infants, more studies are needed to determine long-term effects on safety, proper doses, or even the type of anti-VEGF agent or other drug.

  • Retinopathy of prematurity phenotypes may vary throughout the world based on environmental factors and potential differences in genetic variants. These considerations are important when comparing outcomes from clinical reports after anti-VEGF therapy.

  • Although there is promise

The problem: retinopathy of prematurity is increasing worldwide and has different phenotypes

With increases in preterm births, ROP has become one of the leading causes of childhood blindness worldwide.17 In the United States, ∼14% of childhood blindness is attributed to ROP and in some developing nations estimates are greater than 20%.18 In addition, some countries have developed the ability to save preterm infants but lack resources to regulate oxygen and are experiencing not only cases of ROP from extreme prematurity but also additional cases of ROP in larger and older infants from

Current treatment for retinopathy of prematurity and reasons for better therapies

When ROP was first diagnosed as retrolental fibroplasia in the 1940s in the United States, studies in animal models were performed that revealed that high oxygen at birth was a cause.21 Oxygen damaged newly formed retinal capillaries and led to broad areas of avascular retina.21, 22 When the infant was moved from high oxygen to a relatively hypoxic environment, cells within the avascular retina were stimulated by hypoxia and thought to increase the expression of angiogenic growth factors.23 Now

Toward a treatment solution

It is important to review new evidence regarding the pathophysiology of ROP that has been realized since early studies by Ashton and colleagues,48 Patz,21 and preclinical studies before the FDA approval of anti-VEGF agents in adult diseases. Because it is not possible to safely obtain tissue or vitreous samples from the preterm infant eye to study ROP without risks of bleeding, cataract, or inoperable retinal detachment,42 animal models of OIR have been used. It is important to know strengths

The bevacizumab eliminates the angiogenic threat of retinopathy of prematurity study

Although several clinical series had been reported previously, the Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) was the first published clinical trial that tested intravitreal anti-VEGF antibody, bevacizumab (0.625 mg in 0.025 mL), compared with laser treatment in 150 infants.59 Infants rather than eyes were enrolled to reduce confounding from crossover effects of the antibody. A benefit for infants with zone I/posterior zone II, stage 3+ ROP was

Pro: Evidence That Inhibiting Vascular Endothelial Growth Factor Inhibits Intravitreal Angiogenesis in Severe Retinopathy of Prematurity

ROP has been characterized by 2 phases based on clinical observations and animal models.48, 61, 62 Human ROP also has a third, fibrovascular phase, in which retinal detachment occurs. Few animal models reflect this. The first “epidemic” of ROP occurred in the United States and the United Kingdom in the 1950s. Using a model in kittens, Ashton described phase 1 as high oxygen-induced vaso-obliteration and phase 2 as later hypoxia-induced vasoproliferation.48 Since then, with changes in neonatal

Considerations regarding adult/preterm infant size and dose considerations

No anti-VEGF agent has been FDA-approved for treatment of ROP. Ranibizumab (Genentech) or aflibercept (Regeneron) are the FDA-approved agents for adult eye diseases. The BEAT-ROP clinical trial used bevacizumab, which has not been FDA-approved for any eye disease, but has been tested head-to-head with ranibizumab in a clinical trial for adult AMD and shown to be noninferior.77 Bevacizumab is a humanized monoclonal antibody to VEGF that was tested as an anticancer agent but was not formally

Guidelines if considering anti-vascular endothelial growth factor treatment

Bevacizumab is not FDA-approved. However, there are more studies reported on bevacizumab than on ranibizumab, for which there is no clinical trial for ROP reported to date (Table 7). However, there have been opinions as to which anti-VEGF agent is optimal. Bevacizumab causes longer-term reduction in systemic VEGF levels in adults compared with ranibizumab and, therefore, may be more damaging to the preterm infant. However, in preterm infants, ranibizumab also reduced serum VEGF. Ranibizumab

Future

Studies are ongoing to determine pharmacologic approaches that target signaling downstream of VEGF receptors to safely and effectively inhibit pathologic angiogenesis without interfering with ongoing retinal vascular development. More clinical studies are needed to determine potential safe doses of anti-VEGF agents, and dose escalation studies are being considered. In addition, studies to promote normal retinal vascular development may be considered through the use of nutrients, such as

First page preview

First page preview
Click to open first page preview

References (84)

  • A. Patz

    Oxygen studies in retrolental fibroplasia

    Am J Ophthalmol

    (1954)
  • S. Cunningham et al.

    Transcutaneous oxygen levels in retinopathy of prematurity

    Lancet

    (1995)
  • H. Wang et al.

    Short hairpin RNA-mediated knockdown of VEGFA in muller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity

    Am J Pathol

    (2013)
  • H.A. Mintz-Hittner

    Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors

    Early Hum Dev

    (2012)
  • H. Sone et al.

    Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy

    Life Sci

    (1999)
  • S. Budd et al.

    Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP

    Exp Eye Res

    (2009)
  • G. Zeng et al.

    Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation

    Blood

    (2007)
  • A. Hellström et al.

    Retinopathy of prematurity

    Lancet

    (2013)
  • M.S. Brown et al.

    Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity

    J AAPOS

    (2006)
  • A.J. Churchill et al.

    VEGF polymorphisms are associated with neovascular age-related macular degeneration

    Hum Mol Genet

    (2006)
  • A.C. Bird

    Therapeutic targets in age-related macular disease

    J Clin Invest

    (2010)
  • L.P. Aiello et al.

    Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

    N Engl J Med

    (1994)
  • B. Nicholson et al.

    A review of clinical trials of anti-VEGF agents for diabetic retinopathy

    Graefes Arch Clin Exp Ophthalmol

    (2010)
  • R.W. Cooke et al.

    Genetic polymorphisms and retinopathy of prematurity

    Invest Ophthalmol Vis Sci

    (2004)
  • M. Mititelu et al.

    An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity

    J Pediatr Ophthalmol Strabismus

    (2012)
  • H.A. Mintz-Hittner et al.

    Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity

    N Engl J Med

    (2011)
  • M. Saint-Geniez et al.

    An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris

    Proc Natl Acad Sci U S A

    (2009)
  • M. Saint-Geniez et al.

    Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors

    PLoS One

    (2008)
  • T. Sato et al.

    Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity

    Am J Ophthalmol

    (2012)
  • R. Hoerster et al.

    Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity

    Acta Ophthalmol

    (2013)
  • J. Hu

    Reactivation of retinopathy of prematurity after bevacizumab injection

    Arch Ophthalmol

    (2012)
  • R.D. Patel et al.

    Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity

    Arch Ophthalmol

    (2012)
  • M.J. Bizzarro et al.

    Genetic susceptibility to retinopathy of prematurity

    Pediatrics

    (2006)
  • A. Patz

    Studies on retinal neovascularization. Friedenwald Lecture

    Invest Ophthalmol Vis Sci

    (1980)
  • N. Ashton et al.

    Direct observation of the effect of oxygen on developing vessels: preliminary report

    Br J Ophthalmol

    (1954)
  • N. Ashton

    Editorial: retrolental fibroplasia now retinopathy of prematurity

    Br J Ophthalmol

    (1984)
  • D. Shweiki et al.

    Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

    Nature

    (1992)
  • Group TS-RMS

    Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes

    Pediatrics

    (2000)
  • M.W. Gaynon

    Rethinking stop-ROP: is it worthwhile trying to modulate excessive VEGF levels in prethreshold ROP eyes by systemic intervention? A review of the role of oxygen, light adaptation state, and anemia in prethreshold ROP

    Retina

    (2006)
  • SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network et al.

    Early CPAP versus surfactant in extremely preterm infants

    N Engl J Med

    (2010)
  • B.J. Stenson et al.

    Oxygen saturation and outcomes in preterm infants

    N Engl J Med

    (2013)
  • B. Schmidt et al.

    Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial

    JAMA

    (2013)
  • Cited by (0)

    Disclosure: NIH grants: NEI R01EY017011, NEI R01EY015130. March of Dimes grant: FY-13-75.

    View full text